FDA moves to fast-track review of psilocybin and methylone for mental health
CNN
—
Some psychedelic drugs, once considered fringe, are now getting a step closer to possibly being approved for use as mental health treatments in the United States.
- U.S. FDA plans ultra-fast review of three psychedelic drugs following Trump directive CTV News —
- US FDA plans ultra-fast review of 3 psychedelic drugs after Trump directive South China Morning Post —
- FDA grants quick review for 3 psychedelic drug trials NBC News —
- FDA fast-tracks psychedelic drug research following Trump executive order CNBC —
- FDA plans fast review of 3 psychedelic drugs following Trump directive Boston Globe —